Discordance between CD4 + T-lymphocyte counts and percentages in HIV-infected persons with liver fibrosis

Clinical Infectious Diseases

Volumn 54, Issue 12, 2012, Pages 1806-1813

  Claassen, Cassidy W ^a   Diener West, Marie ^b   Mehta, Shruti H ^a   Thomas, David L ^a,b   Kirk, Gregory D ^a,b  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN;

ADULT; AGED; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; ELASTOGRAPHY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER CIRRHOSIS; LIVER FIBROSIS; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MALE; PRIORITY JOURNAL;

ADULT; CD4 LYMPHOCYTE COUNT; CD4-CD8 RATIO; CD4-POSITIVE T-LYMPHOCYTES; CROSS-SECTIONAL STUDIES; ELASTICITY IMAGING TECHNIQUES; FEMALE; HIV INFECTIONS; HUMANS; LIVER; LIVER CIRRHOSIS; MALE;

EID: 84861510506     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis294     Document Type: Article

References (50)

1. Fahey J, Taylor J, Detels R, et al. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. N Engl J Med 1990; 322:166-72. (Pubitemid 20036390)
2. Hammer SM, Eron JJ Jr, Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008; 300:555-70.
3. Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126:946-54. (Pubitemid 27255797)
4. Vlahov D, Graham N, Hoover D, et al. Prognostic indicators for AIDS and infectious disease death in HIV-infected injection drug users: plasma viral load and CD4+ cell count. JAMA 1998; 279:35-40. (Pubitemid 28070548)
5. Burcham J, Marmor M, Dubin N, et al. CD4 percent is the best predictor of development of AIDS in a cohort of HIV-infected homosexual men. AIDS 1991; 5:365-72.
6. Hulgan T, Raffanti S, Kheshti A, et al. CD4 lymphocyte percentage predicts disease progression in HIV-infected patients initiating highly active antiretroviral therapy with CD4 lymphocyte counts >350 lymphocytes/mm3. J Infect Dis 2005; 192:950-7. (Pubitemid 41266790)
7. Hulgan T, Shepherd BE, Raffanti SP, et al. Absolute count and percentage of CD4+ lymphocytes are independent predictors of disease progression in HIV-infected persons initiating highly active antiretroviral therapy. J Infect Dis 2007; 195:425-31. (Pubitemid 46146121)
8. Taylor JM, Fahey JL, Detels R, Giorgi JV. CD4 percentage, CD4 number, and CD4:CD8 ratio in HIV infection: which to choose and how to use. J Acquir Immune Defic Syndr 1989; 2:114-24. (Pubitemid 19127086)
9. McGovern BH, Golan Y, Lopez M, et al. The impact of cirrhosis on CD4+ T cell counts in HIV-seronegative patients. Clin Infect Dis 2007; 44:431-7. (Pubitemid 46147629)
10. Bongiovanni M, Gori A, Lepri AC, et al. Is the CD4 cell percentage a better marker of immunosuppression than the absolute CD4 cell count in HIV-infected patients with cirrhosis? Clin Infect Dis 2007; 45:650-3. (Pubitemid 47328649)
11. Gandhi RT. Cirrhosis is associated with low CD4+ T cell counts: implications for HIV-infected patients with liver disease. Clin Infect Dis 2007; 44:438-40. (Pubitemid 46151063)
12. Vlahov D, Anthony JC, Munoz A, Margolik J, Celetano D, Solomon L. The ALIVE study: a longitudinal study of HIV-1 infection in intravenous drug users: description of methods. J Drug Issues 1991; 21:759-76.
13. Mehta SH, Lucas G, Astemborski J, Kirk GD, Vlahov D, Galai N. Early immunologic and virologic responses to highly active antiretroviral therapy and subsequent disease progression among HIV-infected injection drug users. AIDS Care 2007; 19:637-45. (Pubitemid 46763739)
14. Giorgi JV, Cheng HL, Margolick JB, et al.; The Multicenter AIDS Cohort Study Group. Quality control in the flow cytometric measurement of T-lymphocyte subsets: the multicenter AIDS cohort study experience. Clin Immunol Immunopathol 1990; 55:173-86. (Pubitemid 20137384)
15. Hoffman RA, Kung PC, Hansen WP, Goldstein G. Simple and rapid measurement of human T lymphocytes and their subclasses in peripheral blood. Proc Natl Acad Sci USA 1980; 77:4914-7.
16. Inglesby TV, Rai R, Astemborski J, et al. A prospective, communitybased evaluation of liver enzymes in individuals with hepatitis C after drug use. Hepatology 1999; 29:590-6. (Pubitemid 29088467)
17. Levine OS, Vlahov D, Koehler J, Cohn S, Spronk AM, Nelson KE. Seroepidemiology of hepatitis B virus in a population of injecting drug users. Association with drug injection patterns. Am J Epidemiol 1995; 142:331-41.
18. McOmish F, Yap PL, Dow BC, et al. Geographical distribution of hepatitis C virus genotypes in blood donors: an international collaborative survey. J Clin Microbiol 1994; 32:884-92. (Pubitemid 24100056)
19. Ziol M, Handra-Luca A, Kettaneh A, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005; 41:48-54. (Pubitemid 40066382)
20. Kirk GD, Astemborski J, Mehta SH, et al. Assessment of liver fibrosis by transient elastography in persons with hepatitis C virus infection or HIV-hepatitis C virus coinfection. Clin Infect Dis 2009; 48: 963-72.
21. Gebo KA, Gallant JE, Keruly JC, Moore RD. Absolute CD4 vs. CD4 percentage for predicting the risk of opportunistic illness in HIV infection. J Acquir Immune Defic Syndr 2004; 36:1028-33. (Pubitemid 38989368)
22. Masur H, Ognibene FP, Yarchoan R, et al. CD4 counts as predictors of opportunistic pneumonias in human immunodeficiency virus (HIV) infection. Ann Intern Med 1989; 111:223-31. (Pubitemid 19190915)
23. World Health Organization. Scaling up antiretroviral therapy in resource-limited settings. Guidelines for a public health approach. Executive Summary. Geneva, Switzerland, April 2002.
24. Babiker AG, Peto T, Porter K, Walker AS, Darbyshire JH. Age as a determinant of survival in HIV infection. J Clin Epi 2001; 54:S16-21. (Pubitemid 34013687)
25. Chaisson RE, Fuchs E, Stanton D, et al. Racial heterogeneity of HIV antigenemia in persons with HIV infection. AIDS 1991; 5:177-80.
26. Egger M, May M, Chene G. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360:119-29. (Pubitemid 34786200)
27. Umeh OC, Currier JS. Sex differences in HIV: natural history, pharmacokinetics, and drug toxicity. Curr Infect Dis Rep 2005; 7:73-8. (Pubitemid 40220531)
28. De Ledinghen V, Douvin C, Kettaneh A, et al. Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr 2006; 41: 175-9.
29. Nguyen-Khac E, Dominique C. Noninvasive diagnosis of liver fibrosis by ultrasonic transient elastography (FibroScan). Eur J Gastroenterol Hepatol 2006; 18:1321-5. (Pubitemid 44737064)
30. Montes ML, Castro JM, Gonzalez J, San Jose Valdes B, Arribas JR. [Relationship between hepatic fibrosis measured by transient elastography and peripheral blood CD4+ lymphocyte values.]. Enferm Infecc Microbiol Clin 2008; 26:561-3.
31. Guiguet M, Kendjo E, Carcelain G, et al. CD4+ T-cell percentage is an independent predictor of clinical progression in AIDS-free antiretroviral-naive patients with CD4+ T-cell counts >200 cells/mm3. Antivir Ther 2009; 14:451-7.
32. Margolick JB, Muñoz A, Donnenberg AD, et al. Failure of T-cell homeostasis preceding AIDS in HIV-1 infection. Nat Med 1995; 1:674-80.
33. Lau B, Gange SJ, Phair JP, Riddler SA, Detels R, Margolick JB. Use of total lymphocyte count and hemoglobin concentration for monitoring progression of HIV infection. J Acquir Immune Defic Syndr 2005; 39:620-5. (Pubitemid 41098480)
34. Liu YK. Effects of alcohol on granulocytes and lymphocytes. Semin Hematol 1980; 17:130-6. (Pubitemid 10088068)
35. Proust J, Rosenzweig P, Debouzy C, Moulias R. Lymphopenia induced by acute bacterial infections in the elderly: a sign of age-related immune dysfunction of major prognostic significance. Gerontology 1985; 31:178-85. (Pubitemid 15037628)
36. Rashkin S, Rouster S, Goodman ZD, Sherman KE. T-helper cells and liver fibrosis in hepatitis C virus-monoinfected patients. J Viral Hepat 2010; 17:222-6.
37. Korner C, Kramer B, Schulte D, et al. Effects of HCV co-infection on apoptosis of CD4+ T-cells in HIV-positive patients. Clin Sci (Lond) 2009; 116:861-70.
38. Streiff MB, Mehta S, Thomas DL. Peripheral blood count abnormalities among patients with hepatitis C in the United States. Hepatology 2002; 35:947-52. (Pubitemid 34258391)
39. Miller MF, Haley C, Koziel MJ, Rowley CF. Impact of hepatitis C virus on immune restoration in HIV-infected patients who start highly active antiretroviral therapy: a meta-analysis. Clin Infect Dis 2005; 41:713-20. (Pubitemid 41170361)
40. Dronda F, Zamora J, Moreno S, et al. CD4 cell recovery during successful antiretroviral therapy in naive HIV-infected patients: the role of intravenous drug use. AIDS 2004; 18:2210-2. (Pubitemid 39463691)
41. Yacisin K, Maida I, Rios MJ, Soriano V, Nunez M. Hepatitis C virus coinfection does not affect CD4 restoration in HIV-infected patients after initiation of antiretroviral therapy. AIDS Res Hum Retroviruses 2008; 24:935-40.
42. Maradona Hidalgo JA, Arribas Castrillo JM, Rodrigo Saez L. [Alcoholic liver cirrhosis, portal hypertension, and behavior of different lymphocyte populations.]. Med Clin (Barc) 1981; 76:211-3.
43. Perrin D, Bignon JD, Beaujard E, Cheneau ML. [Populations of circulating T lymphocytes in patients with alcoholic cirrhosis]. Gastroenterol Clin Biol 1984; 8:907-10. (Pubitemid 15151522)
44. Muller C, Wolf H, Gottlicher J, Eibl MM. Helper-inducer and suppressor-inducer lymphocyte subsets in alcoholic cirrhosis. Scand J Gastroenterol 1991; 26:295-301.
45. Eyster ME, Whitehurst DA, Catalano PM, et al. Long-term follow-up of hemophiliacs with lymphocytopenia or thrombocytopenia. Blood 1985; 66:1317-20. (Pubitemid 16194693)
46. O'Brien TR, Diamondstone L, Fried MW, et al. Idiopathic CD4+ T-lymphocytopenia in HIV seronegative men with hemophilia and sex partners of HIV seropositive men. Am J Hematol 1995; 49:201-6.
47. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. 14 October 2011; 1-167. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed 10 November 2011.
48. El-Sadr WM, Grund B, Neuhaus J, et al. SMART Study Group. Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial. Ann Intern Med 2008; 149:289-99.
49. Wyles DL. Hepatitis virus coinfection in the strategic management of antiretroviral therapy (SMART) study: a marker for non-liver, nonopportunistic disease mortality. Clin Infect Dis 2008; 47:1476-8.
50. Tebaldi E, Peters L, Neuhaus J, et al. Opportunistic disease and mortality in patients coinfected with hepatitis B or C virus in the strategic management of antiretroviral therapy (SMART) study. Clin Infect Dis 2008; 47:1468-75.